» Articles » PMID: 36402451

Value of Threshold Growth As a Major Diagnostic Feature of Hepatocellular Carcinoma in LI-RADS

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2022 Nov 19
PMID 36402451
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: The Liver Reporting and Data System (LI-RADS) version 2018 simplified the definition of threshold growth to '≥50% size increase in a mass in ≤6 months'. However, the diagnostic value of threshold growth for hepatocellular carcinoma (HCC) remained unclear. We evaluated the value of threshold growth, as defined by LI-RADS v2018, in diagnosing HCCs.

Methods: Patients who underwent preoperative gadoxetate disodium-enhanced MRI because of the presence of LI-RADS category 2, 3, or 4 rather than category 5 on prior CT/MRI between January 2017 and December 2020 were retrospectively evaluated. Pathologic or clinical diagnoses were used as reference standards. Imaging features were evaluated by three readers according to LI-RADS v2018. The frequency and diagnostic odds ratio of threshold growth were calculated. The diagnostic performance of LI-RADS category 5 was separately evaluated when threshold growth was and was not considered a major feature, and results were compared using generalized estimation equations. Subgroups of patients who underwent CT/MRI during the previous 3-6 months were analyzed.

Results: Analysis of 340 observations in 243 patients found that the frequency of threshold growth was 18.8% and it gradually increased over time. Threshold growth was significantly associated with HCC (diagnostic odds ratio 5.2; 95% CI 2.1-12.7; p <0.001). Use of threshold growth as a major feature significantly increased sensitivity in both the overall (66.4% vs. 57.3%, p <0.001) and subgroup (73.4% vs. 58.2%, p <0.001) cohorts, but had no effect on specificity in either the overall (97.5% vs. 98.3%, p = 0.319) or subgroup (95.9% vs. 98.0%, p = 0.323) cohorts.

Conclusion: The revised threshold growth of LI-RADS v2018 was significantly associated with HCC. Use of threshold growth as a major diagnostic feature of HCC can improve the sensitivity of LI-RADS v2018.

Impact And Implications: We found that the revised threshold growth in the Liver Imaging Reporting and Data System version 2018 (LI-RADS v2018) was a significant predictor of hepatocellular carcinoma (HCC). The use of threshold growth as a major imaging feature of HCC significantly increased the sensitivity of LI-RADS v2018, especially small HCCs (≤3.0 cm), compared with its non-use. Because these small HCCs are eligible for curative treatments, the additional detection of small HCCs is clinically meaningful.

Citing Articles

Combining CEUS and CT/MRI LI-RADS major imaging features: diagnostic accuracy for classification of indeterminate liver observations in patients at risk for HCC.

Siu Xiao T, Kuon Yeng Escalante C, Tahmasebi A, Kono Y, Piscaglia F, Wilson S Abdom Radiol (NY). 2024; .

PMID: 39438285 DOI: 10.1007/s00261-024-04625-w.


Is concurrent LR-5 associated with a higher rate of hepatocellular carcinoma in LR-3 or LR-4 observations? An individual participant data meta-analysis.

Abedrabbo N, Lerner E, Lam E, Kadi D, Dawit H, Van der Pol C Abdom Radiol (NY). 2024; .

PMID: 39333410 DOI: 10.1007/s00261-024-04580-6.


Clinical impact of CEUS on non-characterizable observations and observations with intermediate probability of malignancy on CT/MRI in patients at risk for HCC.

Kono Y, Piscaglia F, Wilson S, Medellin A, Rodgers S, Planz V Abdom Radiol (NY). 2024; 49(8):2639-2649.

PMID: 38860996 PMC: 11300564. DOI: 10.1007/s00261-024-04305-9.


Performance of LI-RADS category 5 vs combined categories 4 and 5: a systemic review and meta-analysis.

Lee S, Kim Y, Shin J, Shin H, Sirlin C, Chernyak V Eur Radiol. 2024; 34(11):7025-7040.

PMID: 38809263 DOI: 10.1007/s00330-024-10813-5.


Long-term evolution of LR-2, LR-3 and LR-4 observations in HBV-related cirrhosis based on LI-RADS v2018 using gadoxetic acid-enhanced MRI.

Xing F, Zhang T, Miao X, Lu J, Du S, Jiang J Abdom Radiol (NY). 2023; 48(12):3703-3713.

PMID: 37740759 DOI: 10.1007/s00261-023-04016-7.